TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33261915
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (15.5 mg/g)
Study: 34392187
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg orally twice daily
Study: 34214095
Drug: Rotasiil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotasiil (3 doses)
Study: 36069871
Drug: Litifilimab 450
Normalized name: Litifilimab
DrugBank: Litifilimab (DB18864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litifilimab 450 mg
Study: 35075494
Drug: Ningmitai capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningmitai capsule (1.52 g, three times daily)
Study: 34325077
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: resin-modified glass ionomer restoration with no treatment
Study: 35694924
Drug: Olfactory training
Normalized name: BOS TAURUS OLFACTORY BULB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olfactory training (frequent short-term sniffing various odors) for 4 months, performed twice a day
Study: 32272284
Drug: Omalizumab 150
Normalized name: omalizumab 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 150 mg stepped up to 300 mg
Study: 35694107
Drug: FES+MT training
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES+MT training (Functional Electrical Stimulation combined with Mirror Therapy)
Study: 35694107
Drug: MT training
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT training (Mirror Therapy)
Study: 33938678
Drug: e‐pQLB (0.375%
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐pQLB (0.375% ropivacaine + 100 mcg epinephrine, 20 mL each side)
Study: 33938678
Drug: pQLB (0.375%
Approvals — FDA: no, EMA: no, PMDA: no
Description: pQLB (0.375% ropivacaine alone, 20 mL each side)
Study: 35574691
Drug: TQC3564 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3564 single ascending dose (SAD) 25 to 1200 mg
Study: 35574691
Drug: TQC3564 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3564 multiple ascending dose (MAD) 100 or 500 mg, QD
Study: 35574691
Drug: TQC3564 food-effect
Normalized name: Allergenic extract, food, wheat
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC3564 food-effect study 300 mg
Study: 33928916
Drug: KCONVAC 5
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 5 μg/dose
Study: 33928916
Drug: KCONVAC 10
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 10 μg/dose
Study: 33928916
Drug: KCONVAC 5
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 5 μg/dose (0/14 regimen)
Study: 33928916
Drug: KCONVAC 10
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 10 μg/dose (0/14 regimen)
Study: 33928916
Drug: KCONVAC 5
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 5 μg/dose (0/28 regimen)
Study: 33928916
Drug: KCONVAC 10
Normalized name: COV-2 COVID-19 Inactivated Non-US Vaccine Product (Minhai Biotechnology Co, KCONVAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KCONVAC 10 μg/dose (0/28 regimen)
Study: 34666273
Drug: bilateral STN-DBS
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bilateral STN-DBS plus optimal drug therapy (ODT)
Study: 34666273
Drug: optimal drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: optimal drug therapy (ODT) alone
Study: 36296994
Drug: 24 g
Normalized name: glucose 24 g/31 g oral gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 g of fiber/day from 2 buns of 12 g each
Study: 36296994
Drug: 12 g
Normalized name: PEG-12 GLYCERYL LAURATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g of fiber/day from 2 buns of 6 g each
Study: 34371825
Drug: Culinary education
Normalized name: Lens culinaris fruit extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culinary education through 12 weekly 30-min one-on-one telemedicine culinary coaching sessions
Study: 34116166
Drug: Infants reared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infants reared by biological mothers (n = 113)
Study: 33836153
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Study: 35385794
Drug: Mebendazole 500
Normalized name: mebendazole 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 500 mg orally BID for 12 weeks
Study: 32673356
Drug: 80 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp, 320 mgl/ml CM at 4 ml/s (Group B)
Study: 32673356
Drug: 80 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp, 320 mgl/ml CM at 5 ml/s (Group C)
Study: 32673356
Drug: 100 kVp,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp, 400 mgl/ml CM at 4 ml/s (Group A)
Study: 33338971
Drug: alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: alprazolam (1.5 mg daily for 5 days)
Study: 33338971
Drug: etifoxine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: etifoxine (150 mg daily for 5 days)
Study: 35020462
Drug: Dextroamphetamine Transdermal
Normalized name: dextroamphetamine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine Transdermal System (d-ATS) 5 mg patch applied for 9 hours
Study: 35020462
Drug: Dextroamphetamine Transdermal
Normalized name: dextroamphetamine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine Transdermal System (d-ATS)
Study: 34706706
Drug: Spinal manipulative
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal manipulative therapy and home stretching exercises
Study: 32048379
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment for 6 months
Study: 33095213
Drug: Supramolecular ligand
Normalized name: Gallium Ga 68-labeled psma ligand Glu-urea-Lys(ahx)-hbed-CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supramolecular ligand from the drug-candidate library
Study: 32868356
Drug: Pharmacy intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacy intervention pathway - rapid point-of-care HCV PCR test and direct-acting antivirals (DAAs) delivered via pharmacist.
Study: 33978823
Drug: Glasdegib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib plus low-dose cytarabine
Study: 34215599
Drug: LDL-C ≥1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C ≥1.8 mmol/L
Study: 37034344
Drug: LDL-C <1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C <1.8 mmol/L
Study: 32888011
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment recommendation based on anatomical SYNTAX score (SS) between sites and CL
Study: 32888011
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of treatment recommendation based on functional SYNTAX score (SS) between sites and CL
Study: 36177759
Drug: Physical therapist-led
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapist-led care (personalized hip therapy)
Study: 32465861
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 81 mg daily
Study: 33321452
Drug: NTCELL® administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTCELL® administration (putaminal encapsulated porcine choroid plexus cells)
Study: 35018643
Drug: Esketamine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine (0.2 mg/kg)
Study: 32615613
Drug: 2×20 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×20 g carbohydrates (muesli bars)
Study: 32615613
Drug: Preventive carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive carbohydrate administration
Study: 32615613
Drug: 2×10 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×10 g carbohydrates (muesli bars)
Study: 32818917
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant (OAD)
Study: 38557430
Drug: Oral antidepressant
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antidepressant (OAD) plus placebo nasal spray (PBO)
Study: 32283048
Drug: Virtual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Therapy (VT) for 8 weeks, approximately 45 minutes twice weekly on the Jintronix Rehabilitation System
Study: 33218741
Drug: Traditional biological
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional biological valves
Study: 34716201
Drug: SCO-267, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCO-267, a GPR40 Full Agonist
Study: 33258102
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ticagrelor alone)
Study: 38110196
Drug: Voclosporin (23.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voclosporin (23.7 mg twice daily)
Study: 33022048
Drug: Brief behavioral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief behavioral treatment for insomnia (BBTI)
Study: 34915273
Drug: Total carbohydrate
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total carbohydrate (30-g increment)
Study: 32815759
Drug: 20 µg hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg hepatitis B vaccine (IM20 group)
Study: 32815759
Drug: 60 µg hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 µg hepatitis B vaccine (IM60 group)
Study: 32297449
Drug: Background-medication-based individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background-medication-based individualized comparators (BMICs) including enalapril, valsartan, or placebo
Study: 32750571
Drug: Overall anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall anticoagulation treatment
Study: 32198409
Drug: G-CSF group
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF group (82 patients)
Study: 35390539
Drug: Small bowel
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small bowel capsule endoscopy (SBCE) in patients with surgically altered gastric anatomy
Study: 33884731
Drug: Barrier cream/micellar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barrier cream/micellar water
Study: 32440101
Drug: Dupilumab 300mg
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab 300mg subcutaneously administered, added to standard intranasal steroid mometasone furoate, duration of treatment: 24 weeks (SINUS-24) or 52 weeks (SINUS-52) with varying injection frequency.
Study: 35450525
Drug: Medium-term low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medium-term low-dose melatonin
Study: 35450525
Drug: Exogenous melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exogenous melatonin supplements
Study: 35798596
Drug: i-PRF group
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-PRF group (intraarticular injection of injectable platelet-rich fibrin after arthrocentesis)
Study: 33910617
Drug: Nelfinavir 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 750 mg orally, three times daily for 14 days
Study: 35266669
Drug: Implant +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant + connective tissue graft
Study: 32163106
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel and nonpegylated liposomal doxorubicin (PM) with additional carboplatin (PMCb) for TNBC patients
Study: 32163106
Drug: Sequential intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential intense dose‐dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC)
Study: 32163106
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (ERBB2-negative, hormone receptor-positive BC)
Study: 33965683
Drug: Telemedical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedical treatment
Study: 33965683
Drug: On-site treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-site treatment
Study: 32842955
Drug: Midazolam administered
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam administered by a cardiologist
Study: 33473017
Drug: Chloroquine nasal
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine nasal drops (0.03%) administered six times daily (0.5 ml/dose) for 10 days
Study: 32703307
Drug: Dignity therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dignity therapy (DT)
Study: 32448401
Drug: 15 mg/day
Normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/day of prednisolone (PSL)
Study: 32448401
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day of prednisolone (PSL)
Study: 35491532
Drug: Guideline-recommended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended treatment (except for SGLT2 inhibitors)
Study: 35025687
Drug: Compression plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression plus chemotherapy
Study: 34749770
Drug: Topical low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical low-dose calcipotriol ointment (0.05 µg/g)
Study: 32831097
Drug: Robot-assisted neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted neurocognitive hand therapy
Study: 32831097
Drug: Conventional neurocognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional neurocognitive therapy
Study: 35170837
Drug: Optimised minus
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised minus lens (OML) therapy, power ranged between -1.00D and -6.25D
Study: 35170837
Drug: Optimised minus
Normalized name: Arctium minus root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised minus lens (OML) therapy
Study: 35941737
Drug: LNG implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG implant
Study: 34587971
Drug: LNG implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG implant vs IUD
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 12.5 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 10.0-20.0 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 10.0-12.5 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 12.5-15.0 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 10.0 and 12.5 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 7.5-17.5 g kg‐1 diet
Study: 32991991
Drug: Dietary isoleucine
Normalized name: Isoleucine
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary isoleucine (Ile) at 10-12.5 g kg‐1 diet
Study: 34242627
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (behavioral and pelvic floor muscle therapies with midurethral sling surgery)
Study: 34242627
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (for women with Urogenital Distress Inventory irritative scores of ≥50th percentile)
Study: 32757736
Drug: Cosmetic camouflage
Normalized name: Botox Cosmetic
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cosmetic camouflage (daily use for 12 weeks)
Study: 32401072
Drug: Dance/movement therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance/movement therapy (DMT)
Study: 33931953
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol
Study: 34266844
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (IVA) monotherapy with sham photodynamic therapy (n=80)
Study: 34266844
Drug: Aflibercept combined
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) (n=80)
Study: 34229860
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 mcg.kg‐1 (Group F)
Study: 33166032
Drug: Propolis tablets
Normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis tablets at a dose of 250 mg twice daily for 4 months
Study: 34753083
Drug: Cognitive control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive control treatment
Study: 32768403
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 4 mg every 8 hours for 3 days
Study: 33291741
Drug: Trabectedin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin treatment
Study: 34430349
Drug: H1299 lung
Normalized name: BEEF LUNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1299 lung cancer cell lysates (10 mg protein/vaccine) with Iscomatrix™ adjuvant via deep intradermal injection q 4 weeks ×6
Study: 32516765
Drug: Aromatherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy with lavender oil (steam inhalation)
Study: 32171318
Drug: Celebrex treatment
Normalized name: Celebrex
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celebrex treatment
Study: 33681738
Drug: Mifepristone 600
Normalized name: Mifepristone 600 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 600 mg followed by misoprostol 400 μg
Study: 33681738
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by misoprostol 400 μg
Study: 34229364
Drug: DEHP-containing infusion
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEHP-containing infusion sets warmed with blood-fluid warmers
Study: 34229364
Drug: DEHP-free infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEHP-free infusion sets warmed with blood-fluid warmers
Study: 32679728
Drug: 120 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 g/h carbohydrate intake (HIGH)
Study: 32679728
Drug: 90 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 g/h carbohydrate intake (MED)
Study: 32679728
Drug: 60 g/h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g/h carbohydrate intake (LOW)
Study: 32055002
Drug: PSA >0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA >0.2 to ≤4.0 ng/mL
Study: 32055002
Drug: PSA >4.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA >4.0 ng/mL
Study: 35995418
Drug: Synbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic treatment (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin)
Study: 616900538
Drug: Quince syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quince syrup (1 tablespoon/TDS) for 1 week
Study: 616900538
Drug: Vitamin B6
Normalized name: vitamin B6
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B6 tablets (20mg/TDS) for 1 week
Study: 32270633
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received Xingnao Kaiqiao acupuncture at Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Jiquan (HT 1), Chize (LU 5), and Weizhong (BL 40), needles sustained for 30 min, same treatment frequency as observation group
Study: 34419039
Drug: Referral to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral to specialist due to oral problems
Study: 32738935
Drug: live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: live attenuated intranasal pertussis vaccine BPZE1
Study: 34881442
Drug: Hybrid surface
Normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid surface macro-design implants (HS)
Study: 34881442
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants with moderately rough surface (RS)
Study: 34284552
Drug: Sufentanil IN
Normalized name: sufentanil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil IN 0.5 μg kg‐1
Study: 34284552
Drug: Sufentanil IN
Normalized name: sufentanil Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil IN 0.25 μg kg‐1
Study: 34284552
Drug: IV midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV midazolam 0.04 mg kg‐1 and IN 0.9% NaCl (placebo)
Study: 35958557
Drug: Marine long
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine long chain omega-3 polyunsaturated fatty acids (1.1 g EPA + 0.8 g DHA daily)
Study: 33636027
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) without enzalutamide (Cohort 1)
Study: 33636027
Drug: Nivolumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) and enzalutamide (Cohort 2)